Detection of gastrointestinal cancer biomarkers by next-generation mass spectrometry and comprehensive gene expression analysis

我们在这里评估了下一代质谱仪，发现它不适合对血液进行全面的蛋白质分析。因此，我们对血液进行了microRNA分析。为了排除患者之间的个体差异，我们将重点放在本研究中计划接受内镜粘膜切除术（EMR）的食管粘膜癌患者。从3个研究所招募了43名患者。我们分析了从31名患者中收集的治疗前和治疗后血液样本中miRNA的表达。在处理前和处理后样品之间观察到11种miRNAs的表达存在显著差异。我们将在未来的研究中分析30例晚期食管癌患者的这些miRNAs，并评估其作为食管癌生物标志物的有效性。

We here evaluated a next-generation mass spectrometer and found that it not suitable for a comprehensive protein analysis of blood. Therefore, we performed a microRNA analysis of blood. To exclude individual differences between patients, we focused on esophageal mucosal cancer patients who were scheduled to undergo endoscopic mucosal resection (EMR) in the present study. Forty-three patients were recruited from 3 institutes. We analyzed the expression of miRNAs in pre-treatment as well as post-treatment blood samples that were collected from 31 patients. Significant differences were observed in the expression of 11 miRNAs between pre-treatment and post-treatment samples. We will analyze these miRNAs in 30 patients with advanced esophageal cancer in a future study and evaluate their efficacy as biomarkers of esophageal cancer.